000283152 001__ 283152
000283152 005__ 20260108150927.0
000283152 0247_ $$2doi$$a10.1212/NXI.0000000000200542
000283152 0247_ $$2pmid$$apmid:41499725
000283152 037__ $$aDZNE-2026-00048
000283152 041__ $$aEnglish
000283152 082__ $$a610
000283152 1001_ $$00000-0001-5306-7880$$aStascheit, Frauke$$b0
000283152 245__ $$aAberrant Complement Activation Is a Prominent Feature of Chronic Inflammatory Demyelinating Polyneuropathy.
000283152 260__ $$aPhiladelphia, Pa.$$bWolters Kluwer$$c2026
000283152 3367_ $$2DRIVER$$aarticle
000283152 3367_ $$2DataCite$$aOutput Types/Journal article
000283152 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1767881253_14468
000283152 3367_ $$2BibTeX$$aARTICLE
000283152 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000283152 3367_ $$00$$2EndNote$$aJournal Article
000283152 520__ $$aTo comprehensively characterize complement pathway activation in chronic inflammatory demyelinating polyneuropathy (CIDP) and its association with clinical disease features using advanced complement profiling.Complement protein levels indicative of classical, lectin, and alternative pathway activation were quantified by multiplex ELISA and compared between 28 patients with typical CIDP, 24 patients with Charcot-Marie Tooth neuropathy (CMT), and 24 demographically matched healthy controls (HD).Serum levels of activated complement proteins-C3a, C4a, Ba, Bb, C5a, and the soluble terminal complement complex sC5b-9 (sTCC)-were significantly elevated in CIDP patients compared to healthy donors (HD) (p < 0.001). Except for C3a, these protein levels were also significantly higher in CIDP patients than in those with Charcot-Marie-Tooth disease (CMT). Among CIDP patients, those with active, unstable disease exhibited significantly higher levels of terminal complement components (C5a and sTCC) compared to patients with stable disease or in remission (p < 0.001).These findings highlight the critical involvement of aberrant complement activation in the pathophysiology of CIDP and provide a rationale for further investigation into targeted complement inhibition as a therapeutic approach.
000283152 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000283152 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000283152 650_2 $$2MeSH$$aHumans
000283152 650_2 $$2MeSH$$aPolyradiculoneuropathy, Chronic Inflammatory Demyelinating: blood
000283152 650_2 $$2MeSH$$aPolyradiculoneuropathy, Chronic Inflammatory Demyelinating: immunology
000283152 650_2 $$2MeSH$$aPolyradiculoneuropathy, Chronic Inflammatory Demyelinating: physiopathology
000283152 650_2 $$2MeSH$$aMale
000283152 650_2 $$2MeSH$$aFemale
000283152 650_2 $$2MeSH$$aMiddle Aged
000283152 650_2 $$2MeSH$$aComplement Activation: physiology
000283152 650_2 $$2MeSH$$aAdult
000283152 650_2 $$2MeSH$$aCharcot-Marie-Tooth Disease: blood
000283152 650_2 $$2MeSH$$aCharcot-Marie-Tooth Disease: immunology
000283152 650_2 $$2MeSH$$aAged
000283152 7001_ $$0P:(DE-2719)9003388$$aPreßler, Hannah$$b1$$udzne
000283152 7001_ $$00009-0002-7202-0644$$aStein, Kerstin$$b2
000283152 7001_ $$00009-0001-8711-5526$$aPernice, Helena Franziska$$b3
000283152 7001_ $$00000-0002-6013-0072$$aHahn, Katrin$$b4
000283152 7001_ $$00000-0001-7233-5342$$aMeisel, Andreas$$b5
000283152 7001_ $$00000-0002-3007-708X$$aLünemann, Jan D$$b6
000283152 773__ $$0PERI:(DE-600)2767740-0$$a10.1212/NXI.0000000000200542$$gVol. 13, no. 2, p. e200542$$n2$$pe200542$$tNeurology: Neuroimmunology & Neuroinflammation ; official journal of the American Academy of Neurology$$v13$$x2332-7812$$y2026
000283152 8564_ $$uhttps://pub.dzne.de/record/283152/files/DZNE-2026-00048.pdf$$yRestricted
000283152 8564_ $$uhttps://pub.dzne.de/record/283152/files/DZNE-2026-00048.pdf?subformat=pdfa$$xpdfa$$yRestricted
000283152 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9003388$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000283152 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000283152 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEUROL-NEUROIMMUNOL : 2022$$d2024-12-27
000283152 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-27
000283152 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-27
000283152 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-02-13T18:57:06Z
000283152 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-02-13T18:57:06Z
000283152 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2021-02-13T18:57:06Z
000283152 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-27
000283152 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-27
000283152 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-27
000283152 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-27
000283152 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-27
000283152 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bNEUROL-NEUROIMMUNOL : 2022$$d2024-12-27
000283152 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-27
000283152 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-27
000283152 9201_ $$0I:(DE-2719)1810003$$kAG Prüß$$lAutoimmune Encephalopathies$$x0
000283152 980__ $$ajournal
000283152 980__ $$aEDITORS
000283152 980__ $$aVDBINPRINT
000283152 980__ $$aI:(DE-2719)1810003
000283152 980__ $$aUNRESTRICTED